Refeyn

Executive Summary

Refeyn is a UK-based biotechnology company that has developed a novel mass photometry platform for rapid, label-free analysis of single molecules in solution. Founded in 2018 and headquartered in Oxford, the company's technology enables direct measurement of molecular mass and interactions of proteins, antibodies, and viral vectors without the need for labels or surfaces. This capability addresses a critical bottleneck in biopharmaceutical development, where traditional methods like SEC-MALS or SPR are often slow, require labeling, or consume large sample volumes. Refeyn's instruments, such as the Refeyn OneMP, offer researchers a simple, real-time alternative for characterizing sample quality, binding affinities, and stoichiometry, making them particularly valuable in gene therapy, vaccine development, and antibody engineering. With a growing installed base across academic and pharmaceutical labs, Refeyn is well-positioned to capitalize on the expanding demand for biophysical characterization tools. The company has raised significant venture capital to scale manufacturing and expand its commercial reach. However, as a private company, it faces competition from established techniques and newer label-free platforms. Looking ahead, Refeyn's ability to secure additional funding, broaden its product portfolio, and forge strategic partnerships will be key to sustaining growth and capturing market share in the proteomics and diagnostics sectors.

Upcoming Catalysts (preview)

• Q4 2026Series C Funding Round70% success
• Q2 2027Launch of Next-Generation Mass Photometer60% success
• Q3 2026Collaboration with Top 20 Pharma Company50% success